Immunologic Factor
elotuzumab
Brand Names:
Empliciti
Effect:
Increased Immunologic Activity; Increased Lymphocyte Activation
May Treat:
Multiple Myeloma
More Information:
Definitions related to elotuzumab:
-
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.NCI ThesaurusU.S. National Cancer Institute, 2021
-
A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> E
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.